These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21169384)

  • 1. Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin.
    Harradine KA; Kassner M; Chow D; Aziz M; Von Hoff DD; Baker JB; Yin H; Pelham RJ
    Mol Cancer Res; 2011 Feb; 9(2):173-82. PubMed ID: 21169384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
    Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
    Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
    Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
    Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
    Montazami N; Kheir Andish M; Majidi J; Yousefi M; Yousefi B; Mohamadnejad L; Shanebandi D; Estiar MA; Khaze V; Mansoori B; Baghbani E; Baradaran B
    Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):98-103. PubMed ID: 26025411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.
    Lin M; Zhang Y; Li A; Tang E; Peng J; Tang W; Zhang Y; Lu L; Xiao Y; Wei Q; Yin L; Li H
    Oncotarget; 2015 Jun; 6(18):16774-85. PubMed ID: 25904054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
    Gu WJ; Liu HL
    Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
    Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.
    Virag P; Brie I; Fischer-Fodor E; Perde-Schrepler M; Tatomir C; Balacescu O; Irimie A; Postescu ID
    Cell Biochem Funct; 2011 Jul; 29(5):351-5. PubMed ID: 21491469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug.
    Gheidari F; Bakhshandeh B; Teimoori-Toolabi L; Mehrtash A; Ghadir M; Zeinali S
    Anticancer Drugs; 2014 Sep; 25(8):908-16. PubMed ID: 24869759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
    Zeng ZL; Luo HY; Yang J; Wu WJ; Chen DL; Huang P; Xu RH
    Clin Cancer Res; 2014 Feb; 20(4):1042-52. PubMed ID: 24277452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.
    Seyhan AA; Varadarajan U; Choe S; Liu W; Ryan TE
    Mol Biosyst; 2012 Apr; 8(5):1553-70. PubMed ID: 22446932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
    Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells.
    Ozdian T; Holub D; Maceckova Z; Varanasi L; Rylova G; Rehulka J; Vaclavkova J; Slavik H; Moudry P; Znojek P; Stankova J; de Sanctis JB; Hajduch M; Dzubak P
    J Proteomics; 2017 Jun; 162():73-85. PubMed ID: 28478306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.
    Martinez-Cardús A; Martinez-Balibrea E; Bandrés E; Malumbres R; Ginés A; Manzano JL; Taron M; Garcia-Foncillas J; Abad A
    Mol Cancer Ther; 2009 Jan; 8(1):194-202. PubMed ID: 19139129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway.
    Qu Q; Qu J; Guo Y; Zhou BT; Zhou HH
    Anticancer Drugs; 2014 Oct; 25(9):1016-27. PubMed ID: 25075794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
    Boyer J; Allen WL; McLean EG; Wilson PM; McCulla A; Moore S; Longley DB; Caldas C; Johnston PG
    Cancer Res; 2006 Mar; 66(5):2765-77. PubMed ID: 16510598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.